Prolia (Denosumab) Anesthesia and Perioperative Interaction: What Patients and Clinicians Need to Know

Does denosumab interact with anesthetic drugs?

Denosumab is a fully human IgG2 monoclonal antibody that binds RANKL and blocks RANKL-RANK binding, inhibiting osteoclast formation and activity [3][1]. It is given by a healthcare provider as a 60 mg subcutaneous injection once every 6 months for osteoporosis [1].

The label's warnings concentrate on calcium. The boxed warning is about severe hypocalcemia in advanced kidney disease, the warnings section covers hypocalcemia in detail, and the label directs calcium and vitamin D for every patient [1]. For perioperative planning, the clearest labeled concern is hypocalcemia, especially in patients with advanced kidney disease or other risk factors.

What Prolia does to calcium

Denosumab inhibits osteoclast formation and activity, which lowers bone resorption and raises bone density [1]. Serum calcium can fall after a dose.

FREEDOM was a 3-year, randomized, placebo-controlled trial in postmenopausal women aged 60 to 90. The published paper reports enrolling 7,868 women [4], while the Prolia label reports 7,808 women in its trial description [1]. Every participant was instructed to take at least 1,000 mg calcium and 400 IU vitamin D daily [1]. Even so, serum calcium below 8.5 mg/dL at any visit occurred in 1.7% of women on Prolia versus 0.4% on placebo, and the nadir came about 10 days after dosing in women with normal kidney function [1].

A separate 16-week, 55-person study gave a single 60 mg dose across a range of kidney function. Calcium and vitamin D were not initially required but were added during the study; no participant who received adequate supplementation became hypocalcemic, and two participants were hospitalized for intravenous calcium gluconate [5]. The label describes this study in subjects who did not receive calcium and vitamin D: calcium below 7.5 mg/dL or symptomatic hypocalcemia occurred in 0% of those with normal function, 10% with creatinine clearance 50 to 80 mL/min, 29% below 30 mL/min and 29% on hemodialysis [1].

The symptoms the FDA lists for severe hypocalcemia include confusion, seizures, irregular heart rhythm, fainting, face twitching, uncontrolled muscle spasms, and weakness, tingling or numbness [2].

Who is at highest risk around surgery

The boxed warning applies to patients with advanced chronic kidney disease (eGFR below 30), including dialysis-dependent patients, and the label says treatment in these patients should be supervised by a provider with expertise in CKD-mineral and bone disorder [1]. FDA's review found severe hypocalcemia needing emergent treatment at 218.9 per 100,000 person-years with denosumab versus 52.1 with intravenous bisphosphonates and 19.4 with oral bisphosphonates; 8.7% had seizures or arrhythmia and 3.3% died within 30 days [2]. Most cases began 2 to 10 weeks after an injection, with the greatest risk in weeks 2 to 5 [2].

The label also names patients without advanced kidney disease who are predisposed to hypocalcemia: a history of hypoparathyroidism, thyroid surgery or parathyroid surgery, malabsorption syndromes, excision of the small intestine, or treatment with other calcium-lowering drugs. In those patients the label directs that serum calcium, phosphorus and magnesium be assessed 10 to 14 days after a Prolia injection [1].

Xgeva is a separate denosumab product: 120 mg every 4 weeks for cancer-related bone disease. Xgeva has no boxed warning, but its label warns of severe symptomatic hypocalcemia with fatal cases and calls for calcium monitoring especially in the first weeks of therapy [6]. This page is about Prolia.

Timing the injection cycle against surgery

The calcium nadir occurs about 10 days after a dose in normal kidney function [1], and the FDA describes most severe hypocalcemia cases beginning 2 to 10 weeks after an injection, with the highest risk in weeks 2 to 5 [2].

The label's reversibility data describe what follows the last dose: bone turnover rises above pretreatment levels about 9 months after the last Prolia dose and returns to pretreatment values about 24 months after it, and bone mineral density returns to pretreatment values within about 18 months [1].

What the label asks for

• All patients: calcium 1,000 mg daily and at least 400 IU vitamin D daily [1].
• Pre-existing hypocalcemia must be corrected before Prolia is started [1].
• Predisposed patients without advanced CKD: calcium, phosphorus and magnesium 10 to 14 days after the injection [1].
• Advanced CKD, including dialysis: intact PTH, serum calcium, 25(OH) vitamin D and 1,25(OH)2 vitamin D before decisions about treatment, then serum calcium weekly for the first month after an injection and monthly thereafter, supervised by a provider experienced in CKD-MBD [1].
• Pregnancy must be ruled out before each injection [1].

After surgery

Serious infections were more frequent with Prolia than placebo. In the 3-year FREEDOM safety set, nonfatal serious infections occurred in 4.0% of women on Prolia versus 3.3% on placebo, and the label says to advise patients to seek prompt medical attention for signs or symptoms of infection, including cellulitis [1].

Osteonecrosis of the jaw is a labeled risk. The label calls for a routine oral exam before starting Prolia, a dental examination with appropriate preventive dentistry before treatment in patients with risk factors such as invasive dental procedures, cancer, chemotherapy, corticosteroids or poor oral hygiene, and good oral hygiene during treatment; for patients needing invasive dental procedures, the treating physician or oral surgeon guides management on an individual benefit-risk basis [1].

Atypical femoral fractures are also labeled; the label says patients should report new or unusual thigh, hip or groin pain [1].

For joint replacement specifically, a retrospective study using an all-payer national database identified 28,514 osteoporotic patients who had total knee arthroplasty between 2015 and 2022. Aseptic revision at 90 days occurred in 1.2% of patients on denosumab versus 0.6% on bisphosphonates, 0.7% on selective estrogen receptor modulators and 0.9% on teriparatide (p=0.033), and after adjustment denosumab had an odds ratio of 2.17 (p=0.007) for aseptic revision at 90 days [7]. This is a retrospective database analysis and does not establish cause.

Stopping or delaying Prolia around surgery

The label says that if Prolia is discontinued, the patient should be transitioned to an alternative antiresorptive therapy [1]. Stopping denosumab is associated with a higher vertebral fracture rate. Among 1,001 participants who stopped denosumab, the rate rose from 1.2 per 100 participant-years on treatment to 7.1 off treatment, close to the 8.5 seen in people who stopped placebo [8]. Among those with at least one off-treatment vertebral fracture, 60.7% of denosumab stoppers had more than one, versus 38.7% of placebo stoppers, corresponding to a 3.4% versus 2.2% risk of multiple vertebral fractures [8]. This was a post hoc analysis, not randomized.

New vertebral fractures have occurred as early as 7 months after the last dose, on average at 19 months, and a prior vertebral fracture predicts multiple fractures; in the phase 3 trial, 6% of women who stopped and stayed in the study had new vertebral fractures and 3% had multiple new vertebral fractures [1]. A later post hoc analysis put annualized multiple-vertebral-fracture rates at 3.6 per 100 patient-years after placebo, 2.9 after 3 years or less of denosumab and 7.5 after more than 3 years, with longer treatment duration associated with multiple fractures (odds ratio 3.0) [9].

If a dose is delayed around surgery, the label's missed-dose instruction is to give the injection as soon as the patient is available, then every 6 months from that injection [1].

For prescribers planning a transition, an 8-year observational study followed 120 postmenopausal women who received 5 mg zoledronate 6 months after their last denosumab injection. Three vertebral fractures occurred during follow-up (1.1 per 100 patient-years), there were no multiple vertebral fractures, and 66% of the lumbar spine bone density gain and 49% of the total hip gain were retained [10].